Fifth Third Bancorp’s Aurinia Pharmaceuticals AUPH Stock Holding History

Fifth Third Bancorp’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-2,000	Closed	-$44K	–	2678
2021 Q3	$44K	Hold	2,000	–	–	﹤0.01%	1488
2021 Q2	$26K	Hold	2,000	–	–	﹤0.01%	1694
2021 Q1	$26K	Hold	2,000	–	–	﹤0.01%	1673
2020 Q4	$28K	Hold	2,000	–	–	﹤0.01%	1598
2020 Q3	$29K	Hold	2,000	–	–	﹤0.01%	1488
2020 Q2	$33K	Hold	2,000	–	–	﹤0.01%	1429
2020 Q1	$29K	Hold	2,000	–	–	﹤0.01%	1437
2019 Q4	$41K	Hold	2,000	–	–	﹤0.01%	1449
2019 Q3	$11K	Hold	2,000	–	–	﹤0.01%	1770
2019 Q2	$13K	Hold	2,000	–	–	﹤0.01%	1748
2019 Q1	$13K	Hold	2,000	–	–	﹤0.01%	1703
2018 Q4	$14K	Hold	2,000	–	–	﹤0.01%	1683
2018 Q3	$13K	Hold	2,000	–	–	﹤0.01%	1754
2018 Q2	$11K	Hold	2,000	–	–	﹤0.01%	1843
2018 Q1	$10K	Hold	2,000	–	–	﹤0.01%	1888
2017 Q4	$9K	Hold	2,000	–	–	﹤0.01%	1843
2017 Q3	$13K	Hold	2,000	–	–	﹤0.01%	1705
2017 Q2	$12K	Buy	+2,000	New	+$13.5K	﹤0.01%	1678

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

MAM

Melqart Asset Management London, United Kingdom $1.05B AUM 111.55% 1-Year Est. Return

Voloridge Investment Management Jupiter, Florida $23.5B AUM 33.24% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Fifth Third Bancorp's AUPH Position: Q4 2021 in Review

Fifth Third Bancorp sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2021, closing a stake of 2,000 shares — an estimated $44K sold.

Fifth Third Bancorp first reported a position in AUPH in Q2 2017 and held it in 18 quarters. The position peaked at $44K in Q3 2021. 191 funds tracked by Wall St. Rank hold AUPH as of Q4 2021.

Fifth Third Bancorp reported no remaining Aurinia Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Fifth Third Bancorp sold 2,000 Aurinia Pharmaceuticals shares in Q4 2021, an estimated $44K.
Fifth Third Bancorp first reported a position in Aurinia Pharmaceuticals in Q2 2017 and held it in 18 quarters.
Fifth Third Bancorp's Aurinia Pharmaceuticals position peaked at $44K in Q3 2021.
191 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2021.

Based on Fifth Third Bancorp's 13F filing for Q4 2021, filed 1 Feb 2022.